Search

Displaying results 1971 - 1980 of 10000 in total
  1. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC

  2. Drug

    Lonafarnib

    go.drugbank.com/drugs/DB06448
    ApprovedInvestigational

    Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.

  3. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    apo B-containing lipoproteins in the liver and intestines. … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

    Synonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE
  4. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.

  5. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  6. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption. … The dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized.

  7. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    Cetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [A32209]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.

  8. Drug

    Echinacoside

    go.drugbank.com/drugs/DB15488
    Investigational

    [A184577] Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.[A184592] … Echinacoside is a phenylethanoid glycoside isolated from _Echinacea angustifolia_ in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis,

  9. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.

  10. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    It is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Nogapendekin alfa, in combination with inbakicept, mimics the actions of IL-15, , stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which

    Synonyms: Il-15n72d:il-15rec-su/fc soluble complex i, Fusion protein consisting of il-15n72d and il-15rasu/fc